Cook Medical Brings Advanced Endovascular Thoracic Aneurysm Treatment to Canadians

Canadian Approval for Cook`s Advanced TX2 Endograft Reflects Growing Acceptance
of This Device by Physicians Worldwide
BLOOMINGTON, Ind.--(Business Wire)--
In a move reflecting the rapid acceptance of Cook Medical`s advanced endogaft
for thoracic aortic aneurysm worldwide, the company has received approval to
market the Zenith TX2 TAA Endovascular Graft in Canada. Globally, the Zenith TX2
Endovascular Graft is now available in more than 60 markets, including the
United States, Canada, the United Kingdom, European Union, Australia and others
internationally.

"Physicians around the world have made Cook`s Zenith AAA Endograft the world`s
best-selling device of its kind, and we`re now seeing similar momentum in the
growing market for endovascular treatment of thoracic aortic aneurysms," said
Phil Nowell, global leader of Cook`s aortic intervention business unit.

One of Canada`s leading endovascular specialists, Cherrie Abraham, M.D.,
Department of Vascular Surgery, Jewish General Hospital at McGill University,
Montreal, Quebec, said: "This approval is a recognition that this is an
excellent graft that is here to stay. The biggest advantage with TX2 is the
control offered by the tri-fold proximal end. With TX2, we now have the ability
to deploy a graft without the wind-sock effect that is seen with other
commercially approved thoracic stent grafts. I also like that even after
unsheathing the graft, you still have the ability to advance it proximally,
again because of the constrained top end."

U.S. sales of Cook`s TX2 Endograft have increased every month since it received
FDA clearance in June 2008. During that period, approximately 1,000 physicians
at nearly 400 hospitals in the U.S. have requested and received training in the
appropriate use of the TX2, making them eligible to bring the advanced benefits
of this device to numerous patients suffering thoracic aortic aneurysms.

"With sales of the Zenith TX2 Endograft accelerating each month, and the recent
CE Mark approval for our next-generation TX2 Endograft with Pro-Form*, we
believe Cook is on track to achieve market leadership in thoracic aneurysms, as
well."

Just as it is in the United States, the Zenith TX2 Endograft is indicated for
the endovascular treatment of patients with aneurysms or ulcers of the
descending thoracic aorta having vascular morphology suitable for endovascular
repair.

* The TX2 Endograft with Pro-Form is not available for sale in the U.S. or
Canada.

About Cook Medical

Cook Medical was one of the first companies to help popularize interventional
medicine, pioneering many of the devices now commonly used worldwide to perform
minimally invasive medical procedures. Today, the company integrates minimally
invasive medical device design, biopharma, gene and cell therapy and biotech to
enhance patient safety and improve clinical outcomes in the fields of aortic
intervention; interventional radiology; critical care medicine;
gastroenterology;peripheral vascular medicine; bone access and oncology;
interventional cardiology; general surgery and soft tissue repair; urology; and
assisted reproductive technology, gynecology and high-risk obstetrics.Founded in
1963 and operated as a family-held private corporation, Cook is a past winner of
the prestigious Medical Device Manufacturer of the Year Award from Medical
Device & Diagnostic Industry magazine. For more information, visit
www.cookmedical.com.

Cook Medical
David McCarty, 812-339-2235, ext. 2387
Global Director of Public Relations
812-322-1805 (cell)
dave.mccarty@cookmedical.com

Copyright Business Wire 2009